GlassScriptPhysician profile
Michael J Martin
NPI 1750378899
$10,284.26
in general payments reported to CMS, 2019-2025
39 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $1,197 · 2021: $1,733 · 2022: $1,684 · 2023: $1,384 · 2024: $1,580 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,962.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,324.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,157.62 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $982.50 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $934.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.77 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Pfizer INC. | $502.33 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $301.58 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $245.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $240.86 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $203.13 | 2019-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $200.43 | 2019-2025 | Linzess |
| Celgene Corporation | $168.19 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $122.71 | 2024-2025 | Zenpep |
| Fujifilm Healthcare Americas Corporation | $120.07 | 2020 | |
| Qol Medical, LLC | $118.57 | 2020-2023 | Sucraid |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $103.52 | 2024-2025 | Omvoh |
| Amgen INC. | $92.43 | 2022-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $91.06 | 2019-2021 | |
| Daiichi Sankyo INC. | $83.58 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $83.57 | 2021 | |
| Merck Sharp & Dohme LLC | $78.09 | 2019-2023 | Dificid |
| Celltrion USA INC. | $75.30 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $62.31 | 2020-2022 | |
| Biocon Biologics INC | $61.31 | 2024-2025 | Yesintek, Hulio |
| Braintree Laboratories, INC. | $53.25 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $45.42 | 2024-2025 | Terlivaz |
| Medtronic, INC. | $44.58 | 2024-2025 | Interstim |
| Ucb, INC. | $35.46 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $33.06 | 2024-2025 | Iqirvo |
| Pharmacosmos Therapeutics INC. | $32.48 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.27 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $26.47 | 2023 | Zeposia |
| Ethicon US, LLC | $20.29 | 2019 | |
| Alfasigma USA, INC. | $17.36 | 2020 | |
| Coloplast Corp | $17.20 | 2025 | |
| Ardelyx, INC. | $16.23 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $13.94 | 2023 | |
| Novo Nordisk INC | $13.58 | 2025 | Wegovy |
| Echosens North America, INC. | $10.26 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.